The Possible Role of the Novel Cytokines IL-35 and IL-37 in Inflammatory Bowel Disease

Table 1

Demographic and clinical characteristics of IBD patients.

Patients number	Sex	Age at	Disease	Disease; extent	Disease; activity	Current therapy
		diagnosis	duration
		(years)	(months)
					Mayo score
UC1	F	46	4	E2	7	Mesalazine
UC2	M	29	70	E3	12	Mesalazine, corticosteroids
UC3	M	25	2	E3	9	Mesalazine, corticosteroids
UC4	F	51	10	E3	11	Mesalazine, corticosteroids
UC5	M	57	12	E1	5	Mesalazine,
UC6	M	34	6	E2	6	Mesalazine,
UC7	F	28	168	E2	3	Mesalazine,
UC8	M	34	3	E3	11	Mesalazine, corticosteroids
UC9	F	28	40	E2	11	Mesalazine, corticosteroids, and AZA
UC10	M	59	7	E3	11	Mesalazine, corticosteroids
UC11	M	24	1	E3	8	Mesalazine, corticosteroids
UC12	F	27	1	E1	4	Mesalazine, enema
UC13	M	27	1	E1	3	Mesalazine
UC14	M	58	2	E2	12	Mesalazine, corticosteroids
UC15	M	65	2	E2	5	Mesalazine
UC16	F	15	2	E2	11	Mesalazine, corticosteroids
UC17	M	22	12	E3	6	Mesalazine
UC18	M	37	1	E3	3	Mesalazine
UC19	F	63	1	E3	8	Mesalazine
UC20	F	28	5	E3	7	Mesalazine, enema
Average (SEM)		37.85  (3.48)	17.50  (8.76)		7.65  (0.72)
					CDAI score
CD1	M	60	2	L1	7	Mesalazine, corticosteroids, and AZA
CD2	M	39	180	L1	6	Mesalazine, AZA
CD3	M	28	5	L2	8	Mesalazine, corticosteroids
CD4	F	26	1	L3	9	Mesalazine, corticosteroids
CD5	M	49	60	L4	9	Mesalazine, corticosteroids
CD6	M	50	3	L3	6	Mesalazine
CD7	M	22	6	L1	7	Mesalazine, corticosteroids
Average (SEM)		39.15  (5.44)	36.71  (25.18)		7.43  (0.48)

UC: ulcerative colitis; CD: Crohn’s disease; E1: proctitis; E2: leftsided colitis; E3: pancolitis; L1: ileal; L2: colonic; L3: ileocolonic; L4: upper GI involvement; AZA: azathioprine.